Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291354 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL3355426 | 1.00 | ALDH1A1 (0.63) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| Ammonia Solution, Strong SCHEMBL28922498 | 0.98 | ALDH1A1 (0.61) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL6694425 | 0.95 | ALDH1A1 (0.71) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL18779478 | 0.95 | ALDH1A1 (0.71) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL30596558 | 0.95 | ALDH1A1 (0.71) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL14432562 | 0.93 | ALDH1A1 (0.69) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| Formaldehyde SCHEMBL27809950 | 0.90 | ALDH1A1 (0.65) | ALDH1A1HRH3KDM4EPOLBLTA4H | |
| SCHEMBL20588229 | 0.89 | ACHE (0.56) | ALDH1A1HRH3KDM4EHRH2ACHE | |
| SCHEMBL6853255 | 0.89 | ACHE (0.56) | ALDH1A1HRH3KDM4EHRH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-01-06 | — | — | EP | claimed |
| WO-2014131777-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-09-04 | — | — | WO | claimed |
| EP-0462696-B1 | Novel pyrido [2,3-f][1,4] thiazepines and pyrido [3,2-b][1,5] benzothiazepines | ORTHO PHARMA CORP (US) | 1995-08-09 | — | — | EP | claimed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022256554-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | UNIVERSITY OF THE SCIENCES (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-112204037-A | Novel oxoquinolizine compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2020056089-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| US-7807426-B2 | Processes for producing optically active 1-substituted 2-methylpyrrolidine | KANEKA CORPORATION (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156824-A1 | Hydroamination of Alkenes | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-06-18 | — | — | US | disclosed |
| US-20070292926-A1 | Processes for Producing Optically Active 1-Substituted 2-Methylpyrrolidine and Intermediate Therefor | KANEKA CORPORATION (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1715054-A1 | PROCESSES FOR PRODUCING OPTICALLY ACTIVE 1-SUBSTITUTED 2-METHYLPYRROLIDINE AND INTERMEDIATE THEREFOR | KANEKA CORPORATION (JP) | 2006-10-25 | — | — | EP | disclosed |
| CN-1764451-A | Process for the preparation of 5-methyl-N- (methyl aryl) -2-pyrrolidone, 5-methyl-N- (methyl cycloalkyl) -2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone | DU PONT (US) | 2006-04-26 | — | — | CN | disclosed |
| EP-1122257-B1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156824-A1 | Hydroamination of Alkenes | HRH3, HRH4, H1-3 | ALDH1A1 904/4885HRH3 1/4885KDM4E 2924/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | ALDH1A1 4344/4885HRH3 4242/4885KDM4E 674/4885 |
| US-20070292926-A1 | Processes for Producing Optically Active 1-Substituted 2-Methylpyrrolidine and Intermediate Therefor | FAR1, NOTUM, ALDH7A1 | ALDH1A1 75/4885HRH3 2714/4885KDM4E 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.